3-year survival rate increased to 85% in BCR::ABL1-negative B-cell leukemia patients receiving consolidation chemotherapy with experimental blinatumomab.
The New England Journal of Medicine published a practice-changing finding from the phase 3 study E1910, revealing a significant survival improvement for adults with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. Those who received additional standard consolidation chemotherapy with experimental blinatumomab had an 85% survival rate at 3 years, compared to 68% in those who had chemotherapy only. Blinatumomab, a Bispecific T-cell Engager immuno-oncology therapy, targets CD19 surface antigens on B cells, helping the immune system detect and target malignant cells.
July 24, 2024
4 Articles